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Roy B. Jones,1 Yago Nieto,1 Donna Wall,2 John R. Wingard,3 J. Douglas Rizzo,4
Philip L. McCarthy, Jr.,5 Denise Oliansky,5 Theresa Hahn5INTRODUCTION
In 1999, the American Society for Blood and Mar-
row Transplantation (ASBMT) began the develop-
ment of systematic evidence-based reviews and
position statements on the effectiveness of autologous
and allogeneic hematopoietic stem cell transplantation
(SCT) for specific diseases. The purpose of these re-
views is to achieve broader and more consistent cover-
age from payers for established indications for SCT,
and provide evidence in support of clinical decisions
and matters of public policy regarding SCT. The
ASBMTEvidence-Based Review SteeringCommittee,
chaired by Dr. Roy Jones, developed a policy outlining
the methodology to be followed for these reviews [1].
Evaluation of this process after the completion of the
first two reviews resulted in a revised policy statement
in 2005 [2], which focused the reviewprocess to address
questions most relevant to clinicians and scientists.
Currently, seven reviews have been published inBiology
of Blood and Marrow Transplantation on the use of SCT
in the therapy of: diffuse large B-cell non-Hodgkin
lymphoma (NHL) [3], multiple myeloma (MM) [4],
pediatric acute lymphoblastic leukemia (ALL) [5],
adult ALL [6], pediatric acute myelogenous leukemia
(AML) [7], adult AML [8], and myelodysplastic syn-
dromes (MDS) [9].1M.D. Anderson Cancer Center, Houston, Texas; 2Texas
plant Institute, San Antonio, Texas; 3University of Florida
h Science Center, Gainesville, Florida; 4Medical College
isconsin, Milwaukee, Wisconsin; and 5Roswell Park
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6/j.bbmt.2009.02.008The ASBMT Evidence-Based Review Steering
Committee has determined that previous reviews should
be updated regularly at approximately 5-year intervals.
Updated reviews will provide current summaries of the
evidence and timely treatment recommendations, and
will determine if recent clinical evidence strengthens
or changes the treatment recommendations provided
in the reviews at the time of first publication. To guide
its own activities and that of the expert panels associated
with each review, the ASBMT Evidence-Based Review
Steering Committee has developed this policy state-
ment regarding the Methodology for Updating Published
Evidence-Based Reviews Evaluating the Role of Blood and
Marrow Transplantation in the Treatment of Selected
Diseases. The following statement has been submitted
to and accepted by the ASBMT Executive Committee.
THE PROCESS FOR UPDATING PREVIOUSLY
PUBLISHED REVIEWS
Expert Panel Selection
For updating prior reviews, the original expert pan-
elists will be invited to participate in the update. In the
event that members of the original panels are unavail-
able, new panelists will be nominated by the EBR Steer-
ing Committee and invited to participate as needed.
Presentation of New Evidence
New evidence published since the completion of the
initial review will be presented in text format in the up-
dated review,while referencing the previously published
review.Summary tableswill includeall previousdata and
be updated to reflect new evidence. An updated Treat-
ment Recommendations table will indicate whether
each recommendation is new, changed, or unmodified
since the previous review, and whether the supporting
evidence for recommendations in the original review
are unchanged or strengthened since the last review.761
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Updates will occur in the same order as the publi-
cation of the original reviews, unless there is a substan-
tial reason to promote the order of a specific review.
The first update will address the clinical evidence on
diffuse large B-cell NHL that has been published since
2001. Updated reviews will be published at the rate of
one per year, in addition to new review topics pub-
lished at the rate of one per year.
Summary
At its best, evidence-based medicine advances its
field of inquiry and points toward research that will
lead to better diagnostic and treatment options. By
updating previously published evidence-based reviews
and their treatment recommendations, physicians will
have access to timely information that will facilitate
and help disseminate advances in the field of transplan-
tation. The goal is to provide every patient access to
the treatment options that offer the best chance for
survival and a high quality of life.REFERENCES
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